MedElevator
Войти в исследования POSC374 Association of COVID-19 on Adherence to Oral Specialty Pharmacy Oncology Medications and Quality of Life of Multiple Myeloma Patients
Аннотация
Аннотация не предоставлена источником. Содержательный обзор этой публикации недоступен.
Перевод полного текста: Перевод в очереди
Полный текст источника
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Objectives
In winter of 2019-2021 SARS-CoV-2 became pandemic (CoVID-19 or P). During P, treating patients with chronic disease burden, i.e., cancer (O), with multiple myeloma (MM) oncologics and achieving high medication adherence was reported to be challenging, e.g., delayed/missed provider visits, prescriptions, lab tests, and P-related financial difficulties and feelings of depression or anxiety. There are two Objectives: that characterize how the P may be associated with changes in: 1. adherence to specialty pharmacy MM medications (O-SP-D) and 2. MM patient-reported quality of life (QoL).
Methods
A retrospective, observational, pre-/post- design study of 199 USA MM patients’ adherence to MM-SP-D and their reported QoL was conducted Pre-P (1/1-12/31/2019) and Post-P (3/1-8/31/2020). Patient assessments(PA), including medication therapy management (SPMTM) and the EQ-5D-5L QoL instrument, occurred at start-of-care (SOC) and 7-10 days before refills (F-U). Descriptive statics were used to calculate Pre-P Dimensional means before and after starting O-SP-D with SPMTM and again at F-U Post-P. The means of QoL measures in the Pre-P and Post-P periods were compared for differences, representing improved or diminished QoL associated with P. The mean medication possession ratio (MPR or adherence) was calculated, using the F-U from Pre-P and Post-P.
Results
MPR was 1.0 Pre-P and 0.999 during Post-P (0.1% decrease). Differences between QoL means Pre-P vs Post-P were: Mobility +0.657 (65.7%), Self-Care +0.538 (53.8%), Usual Activities +0.642 (64.2%), Pain/Discomfort+0.884 (88.4%), Anxiety/Depression +0.641 (64.1%), Overall Health State +16.0 (16%). Plus “+” is decreased/worsened in Dimensions 1-5; Positive “+” is improvement in Overall Health State.
Conclusions
Post-P MPR decreased 0.1% compared to Pre-P, and both were higher than the industry standard of 0.8. On average MM patients reported decreases all QoL Dimensions Post-P compared to Pre-P. Explanations associated with the decreases are suggested. Additional studies are suggested.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.